Circulation. 2023 Apr 25;147(17):1317-1343. doi: 10.1161/CIR.0000000000001136. Epub 2023 Mar 16.
Pulmonary hypertension, defined as an elevation in blood pressure in the pulmonary arteries, is associated with an increased risk of death. The prevalence of pulmonary hypertension is increasing, with an aging population, a rising prevalence of heart and lung disease, and improved pulmonary hypertension survival with targeted therapies. Patients with pulmonary hypertension frequently require noncardiac surgery, although pulmonary hypertension is associated with excess perioperative morbidity and death. This scientific statement provides guidance on the evaluation and management of pulmonary hypertension in patients undergoing noncardiac surgery. We advocate for a multistep process focused on (1) classification of pulmonary hypertension group to define the underlying pathology; (2) preoperative risk assessment that will guide surgical decision-making; (3) pulmonary hypertension optimization before surgery to reduce perioperative risk; (4) intraoperative management of pulmonary hypertension to avoid right ventricular dysfunction and to maintain cardiac output; and (5) postoperative management of pulmonary hypertension to ensure recovery from surgery. Last, this scientific statement highlights the paucity of evidence to support perioperative pulmonary hypertension management and identifies areas of uncertainty and opportunities for future investigation.
肺动脉高压是指肺动脉内血压升高,与死亡风险增加相关。随着人口老龄化、心脏病和肺部疾病发病率上升以及靶向治疗改善肺动脉高压患者的生存,肺动脉高压的患病率正在增加。肺动脉高压患者常需接受非心脏手术,但肺动脉高压与围手术期发病率和死亡率升高相关。本科学声明就非心脏手术患者肺动脉高压的评估和管理提供指导。我们倡导采用多步骤流程,重点关注:(1) 分类肺动脉高压组别,以明确潜在病理;(2) 术前风险评估,以指导手术决策;(3) 手术前优化肺动脉高压,以降低围手术期风险;(4) 术中管理肺动脉高压,以避免右心室功能障碍和维持心输出量;(5) 术后管理肺动脉高压,以确保手术恢复。最后,本科学声明强调了支持围手术期肺动脉高压管理的证据不足,并确定了不确定领域和未来研究机会。